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See Article, pages 381–388Hepatocellular carcinoma (HCC) is a common cancer accounting
for a signiﬁcant proportion of all cancers worldwide. Although
most cases of HCC occur in countries where hepatitis B virus
(HBV) and hepatitis C virus (HCV) infections are endemic, the
tumour is ubiquitous and one of the most challenging complica-
tions of advanced liver disease. HCC develops deviously and there
are currently no reliable biomarkers for early diagnosis. Indeed,
because alpha-foetoprotein (AFP) has poor sensitivity and speci-
ﬁcity, and other serological markers such as des-gamma-carb-
oxyprothrombin (DCP), and Lens culinaris agglutinin-reactive
fraction of AFP (AFP-L3) perform only slightly better [1], abdom-
inal ultrasound is presently considered the tool of choice for sur-
veillance of patients at risk. Treatment of HCC has considerably
improved over the last few decades from mere surgical resection
in a minority of patients with good hepatic function and small
tumours to orthotopic liver transplantation in selected patients
satisfying the stringent Milan criteria [2], to locoregional ablation
procedures, transarterial chemoembolization, and more recently
antiangiogenetic drugs that increase survival in patients with
advanced HCC for whom no therapy was hitherto available. Tar-
geted treatment options are expected to expand exponentially as
speciﬁc molecular signatures are being identiﬁed for HCC sub-
groups deﬁned by microarray analysis [3]. Despite the wealth
of information on molecular biology, tumour growth rate, sur-
veillance, diagnosis and management, there is currently only a
scarcity of seminal studies addressing the immunopathogenesis
of HCC, which may have important implications in the design
of immunotherapeutic strategies. With respect to adaptive
immunity it has been suggested that antigens such as AFP, the
melanoma-associated antigen (MAGE), glypican 3 and NY-ESO,
which are highly expressed in HCC (reviewed in [4]), are potential
targets for T-cell responses. Moreover, several studies suggested
that the presence of tumour-inﬁltrating cytotoxic T-cells is indic-
ative of better survival. Interestingly, treatment of neoplastic
nodules with radiofrequency thermal ablation (RFTA) can
enhance the release and exposure of tumour antigens, which
might help to overcome immune tolerance towards cancer cells
[5]. Innate immune responses have only been marginallyJournal of Hepatology 20
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essential component of innate immunity being instrumental in
anti-tumour immune responses [6]. A recent study provided
important evidence in favour of their role in HCC, with increased
frequencies of NK cells expressing higher levels of activating and
reduced levels of inhibitory NK receptors, together with increased
functional activity, e.g. interferon-c production and cytotoxicity,
in patients treated with RFTA [7]. Interestingly, recurrence-free
survival correlated with sustained functional NK cell activation,
suggesting a role for these cells in the control of liver cancer.
In this issue of the Journal, Kamimura et al. take a fresh look at
the role of NK cells in HCC by examining correlates of natural-
killer group 2, member D (NKG2D) ligand expression and tumour
recurrence. NKG2D is a fundamental activating receptor belong-
ing to the C-type lectin-like family which is constitutively
expressed on NK cells, most NKT cells, some cdT and CD8 T cells
(reviewed in [8]), and unlike other NKG2 receptors, does not
associate with CD94. The seemingly invariant activating receptor
NKG2D promiscuously binds to multiple ligands such as major
histocompatibility complex class I-related chain A and B (MICA/
B) and the unique long 16 (UL16)-binding protein family (ULBPs)
that are poorly, if at all expressed on healthy cells but they are
up-regulated by stress, viral infection or DNA damage [9]. Up-
regulation of these ligands may tip the balance of NK cells from
inhibition to activation (‘‘induced self’’ recognition) with obvious
biological implications. The authors show that one of the major
NKG2D ligands, ULBP1, was not expressed on poorly differenti-
ated human HCC tissue and on a similarly poorly differentiated
HCC cell line, whereas it was abundantly expressed on dysplastic
nodules and well to moderately differentiated HCC. Moreover,
loss of ULBP1 expression was not related to reduced mRNA
expression suggesting that post-transcriptional events were
responsible for it. Indeed, evidence in support of their hypothesis
came from proteasome inhibition experiments which resulted in
upregulation of ULBP1. More importantly, recurrence-free sur-
vival, even though not the overall survival, was signiﬁcantly
shorter in patients with ULBP1-negative tumours and loss of
ULBP1 was an independent predictor of early recurrence. These
ﬁndings provide corroborative evidence in favour of a role of
NK cells and, more speciﬁcally of the NKG2D receptor pathway,
in liver cancer immune surveillance.
A complex interplay between NKG2D and its ligands may be
involved in the natural history and response to treatment in a
variety of cancers, including HCC [8,10]. However, although12 vol. 56 j 308–310
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Fig. 1. Mechanisms of inhibition of NK cell killing of tumour cells via the
NKG2D receptor/ligand(s) pathway. Inhibition can occur by down-regulation of
ligand(s) on target cells or by down-modulation of NKG2D on effector cells via
shed ligand(s).
JOURNAL OF HEPATOLOGYNKG2D ligand expression on cancer cells is generally associated
with indolent disease progression and prolonged survival in sev-
eral types of tumour [11], increased ligand shedding may be one
mechanism responsible for NKG2D down-regulation, decreased
cytotoxic potential and tumour progression, at least when soluble
MICA is released in excess by neoplastic cells, as shown in some
oncological settings including HCC [12–14]. Alternatively, as
described by Kamimura, down-regulation of ligands such as
ULBP1 may prevent effective NKG2D killing and promote cancer
recurrence (Fig. 1). An additional aspect of the potential impor-
tance of the subversion of the NKG2D functional pathway per-
tains to chronic hepatitis C virus (HCV) infection which is
responsible for cirrhosis and HCC in the majority of patients in
the Western world and Japan. Indeed, it has recently been shown
that the HCV NS5A protein stimulates the production of IL-10
which in turn triggers the secretion of TGF-b that down-modu-
lates NKG2D expression on NK cells [15]. This may have further
impact on the subgroup of patients developing HCC in the con-
text of a chronic HCV infection.
Although NKG2D-ligand interaction appears to be an impor-
tant pathway of cancer control mediated by NK cells, the expres-
sion of several other ligands of activating and inhibitory NK
receptors may also play a role in controlling liver carcinogenesis.
For the former, DNAM-1, which has been shown to play a role
together with NKG2D in NK killing of Ewing’s sarcoma cells
[16] has been acknowledged to potentially be involved in HCC
[17]: This is particularly relevant to Kamimura’s study, since
NK cell degranulation could not be effectively inhibited by anti-
ULBP1 blockade. However, antibody blocking is usually not as
effective as silencing with speciﬁc siRNAs and this may, to some
extent, have inﬂuenced the data. Nonetheless, it would be naïve
to ignore the role of other activating receptors such as NKp30,
NKp44, and NKp46, although their ligands are far less deﬁned
than those of NKG2D [18]. Furthermore, the role of HLA/killer
immunoglobulin-like inhibitory receptors (KIR) match, has been
largely overlooked. To this end, it may be inferred that individu-Journal of Hepatology 201als homozygous for weak KIR-ligand combinations are more
likely to counteract proliferation of HCC, since NK cell inhibition
is more easily overcome in patients with weak KIR-ligand bind-
ing, allowing more effective lysis of tumour cells.
It is now time that immunotherapy of liver cancer be rescued
from neglect or experimental stage in animal models. Growing
evidence indicate that manipulation of innate immune responses
could be a viable option and one possibility would be to activate
NK cells ex vivo to upregulate NKG2D (or other activating recep-
tors), to induce ligand expression on tumour tissue in vivo, or
both. Infusion of activated allogeneic NK cells, which do not
require identiﬁcation of tumour antigens, antigen priming, or
vaccination strategies and do not cause graft vs. host disease,
should be considered for proof-of-concept studies of HCC immu-
notherapy. Recent studies suggest that proteasome inhibitors,
such as bortezomib or MG132 may render HCC and other
tumours more susceptible to NKG2D- (as also shown here) or
tumour necrosis factor-related apoptosis-inducing ligand
(TRAIL)-mediated cell lysis [19]. This may represent a valid appli-
cation of adjuvant immunotherapy for patients treated with loco-
regional ablative therapies or with chemotherapeutic agents able
to sensitize HCC cells to NK lysis. To this end, sorafenib has been
shown to reduce MICA shedding, which inhibits NKG2D-medi-
ated killing [20]. A better understanding of NK cell-mediated
HCC immune surveillance will help in the design of innovative
therapeutic approaches in a ﬁeld that has for long relied on rather
primitive treatment aids. The stakes are too high for us to afford
to fail the challenge.Conﬂict of interest
The author declared that he does not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.References
[1] Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic
accuracy of tumor markers for hepatocellular carcinoma: a systematic
review. Hepatol Int 2008;2:17–30.
[2] Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al.
Predicting survival after liver transplantation in patients with hepatocellular
carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.
Lancet Oncol 2009;10:35–43.
[3] Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma.
Gastroenterology 2011;140:1410–1426.
[4] Fatourou EM, Koskinas JS. Adaptive immunity in hepatocellular carcinoma:
prognostic and therapeutic implications. Expert Rev Anticancer Ther
2009;9:1499–1510.
[5] Zerbini A, Pilli M, Fagnoni F, Pelosi G, Pizzi MG, Schivazappa S, et al.
Increased immunostimulatory activity conferred to antigen-presenting cells
by exposure to antigen extract from hepatocellular carcinoma after radio-
frequency thermal ablation. J Immunother 2008;31:271–282.
[6] Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225–274.
[7] Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, et al.
Radiofrequency thermal ablation for hepatocellular carcinoma stimulates
autologous NK-cell response. Gastroenterology 2010;138:1931–1942.
[8] Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene
2008;27:5944–5958.
[9] Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune
responses. Immunol Rev 2010;235:267–285.
[10] Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, et al.
Natural killer cell-mediated lysis of hepatoma cells via speciﬁc induction of
NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Cancer Res 2005;65:6321–6329.2 vol. 56 j 308–310 309
Editorial
[11] McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, et al. NKG2D
ligand expression in human colorectal cancer reveals associations with
prognosis and evidence for immunoediting. Clin Cancer Res
2009;15:6993–7002.
[12] Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E, et al.
Altered NKG2D function in NK cells induced by chronic exposure to NKG2D
ligand-expressing tumor cells. Blood 2005;106:1711–1717.
[13] Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands
impair expression of NKG2D and T-cell activation. Nature
2002;419:734–738.
[14] Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S,
et al. Impairment of natural killer cell and dendritic cell functions by the
soluble form of MHC class I-related chain A in advanced human hepatocel-
lular carcinomas. J Hepatol 2005;43:1013–1020.
[15] Sène D, Levasseur F, Abel M, Lambert M, Camous X, Hernandez C, et al. PLoS
Pathog 2010;6:e1001184.310 Journal of Hepatology 201[16] Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM,
Gelderblom H, et al. NK cells recognize and lyse Ewing sarcoma cells through
NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol
2008;45:3917–3925.
[17] Toutirais O, Cabillic F, Le Friec G, Salot S, Loyer P, Le Gallo M, et al. DNAX
accessory molecule-1 (CD226) promotes human hepatocellular carcinoma
cell lysis by Vgamma9Vdelta2 T cells. Eur J Immunol 2009;39:1361–1368.
[18] Mondelli MU, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis:
facts and controversies. Eur J Clin Invest 2010;40:851–863.
[19] Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, et al.
Sensitization of tumor cells to NK cell-mediated killing by proteasome
inhibition. J Immunol 2008;180:163–170.
[20] Kohga K, Takehara T, Tatsumi T, Ishida H, Miyagi T, Hosui A, et al. Sorafenib
inhibits the shedding of major histocompatibility complex class I-related
chain A on hepatocellular carcinoma cells by down-regulating a disintegrin
and metalloproteinase 9. Hepatology 2010;51:1264–1273.2 vol. 56 j 308–310
